Aridis Pharmaceuticals

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in Los Gatos, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using human monoclonal antibodies, or mAbs, to treat infections. The company was founded by Eric J. Patzer and Vu L. Truong on April 24, 2003 and is headquartered in Los Gatos, CA.

LOS GATOS, Calif., Dec. 21, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that Vu Truong, Ph.D.

Aridis Pharmaceuticals CEO Discusses Monoclonal Antibody Cocktail Protection Against COVID-19 Omicron Variant and Other Viruses in Fox Business Interview

Aridis Pharmaceuticals has a new cocktail, and it may be the ticket out of the omicron variant. Here's why ARDS stock is worth watching.

ARDS Stock Alert: The Covid-19 News Sending Aridis Skyrocketing Today

Quoin Pharmaceuticals Ltd

Reliance Global Group

Making a penny stocks watchlist today? Check these three out The post Best Penny Stocks to Buy as 2021 Ends?

Best Penny Stocks to Buy as 2021 Ends? 3 to Watch Right Now

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) stock is surging after announcing encouraging preclinical data for pan coronavirus fully human monoclonal antibody (mAb) cocktail AR-701. The data show that the antibody is broadly reactive against the omicron and other COVID-19 variants, SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome Coronavirus), and seasonal ('common cold') human coronaviruses.

Aridis Stock Rallies After Positive Preclinical Data For COVID-19 Antibody Against Omicron

The stock price of Aridis Pharmaceuticals Inc (NASDAQ: ARDS) increased by over 105% pre-market today. This is why it happened.

Aridis Pharmaceuticals Stock (ARDS): Why The Price Surged Today

LOS GATOS, Calif., Dec. 21, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that its fully human monoclonal antibody (mAb) cocktail AR-701 is broadly reactive against the Omicron and other COVID-19 (SARS-CoV-2) variants, SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome Coronavirus), and seasonal ('common cold') human coronaviruses.

Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses

LOS GATOS, Calif., Nov. 10, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2021.

Aridis Pharmaceuticals Announces Third Quarter 2021 Results

ARIDIS PHARMACT (ARDS) delivered earnings and revenue surprises of 3.51% and -91.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ARIDIS PHARMACT (ARDS) Reports Q2 Loss, Misses Revenue Estimates

LOS GATOS, Calif., Aug. 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its second quarter ended June 30, 2021.

Aridis Pharmaceuticals Announces Second Quarter 2021 Results

ARIDIS PHARMACT (ARDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate ARIDIS PHARMACT (ARDS) to Report a Decline in Earnings: What to Look Out for

LOS GATOS, Calif., Aug. 2, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,947,556 shares of the Company's common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 2,473,778 shares of the Company's common stock, at an effective purchase price of $5.053 per share of common stock (or common stock equivalent) and associated warrant, in a registered direct offering priced at-the-market under Nasdaq rules.

Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market

LOS GATOS, Calif., July 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that animal efficacy data reported by the Coronavirus Immunotherapeutics Consortium (CoVIC) showed that the Company's COVID-19 monoclonal antibody (mAb) AR-711, one of two mAbs in the AR-712 cocktail, ranks among the top 5 most potent mAbs that the CoVIC consortium have studied to date.

Aridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC)

AstraZeneca

LOS GATOS, Calif., July 19, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to in-license the late stage monoclonal antibody candidate, suvratoxumab.

Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca

Aridis Pharmaceuticals' (ARDS) inhaled COVID-19 dual antibody cocktail treatment, AR-712, binds and neutralizes the Delta variant of the virus. Stock rises in after-hours trading.

Aridis' (ARDS) COVID Antibody Combo Neutralizes Delta Variant

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has announced that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant of COVID-19 at a highly effective level (~20ng/mL).  Binding analyses project that AR-712 will be effective against all variants on the U.S. CDC's variants of interest and concern lists.

Aridis Pharma's COVID-19 Antibody Neutralizes Delta Variant In Animal Model

LOS GATOS, Calif., July 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant virus SARS-CoV-2 at a highly effective level (~20ng/mL).

Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant

ARIDIS PHARMACT (ARDS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Strength Seen in ARIDIS PHARMACT (ARDS): Can Its 10% Jump Turn into More Strength?

LOS GATOS, Calif., May 11, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the first quarter ended March 31, 2021.

Aridis Pharmaceuticals Announces First Quarter 2021 Results

PARAMUS, N.J.--(BUSINESS WIRE)--Kermode Biotechnologies, Inc., announced that it is actively engaged in discovery to identify the mode of transmission and replication for the ASFV.

CORRECTING and REPLACING Kermode Biotechnologies Announced that it is Actively Engaged in Discovery to Identify the Mode of Transmission for the African Swine Fever Virus (ASFV)

Kermode Biotechnologies Announced that it is Actively Engaged in Discovery to Identify the Mode of Transmission for the African Swine Fever Virus (ASFV)

LOS GATOS, Calif., March 30, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the fourth quarter ended December 31, 2020.

Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update

LOS GATOS, Calif., March 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced an interview with Vu Truong, Ph.D.

Aridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has entered into an out-licensing and product discovery agreement with a privately-held Kermode Biotechnologies Inc. Kermode works on vaccines and mAbs for zoonotic viruses, which are animal viruses that can infect humans.

Aridis, Kermode Enter In Licensing And Discovery Agreement For Zoonotic Viruses

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has added its inhaled AR-711 monoclonal antibody with a second antibody, AR-713, designed to neutralize newly emerging COVID-19 mutated variants. The company says that the cocktail referred to as AR-712 will provide broad coverage of all known high-risk strains.

Aridis Pharma To Test Inhaled Antibody Cocktail In COVID-19 Variants

LOS GATOS, Calif., Feb. 23, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that it has augmented its inhaled...

Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants

News for Aridis Pharmaceuticals Stock (ARDS)